X-FAB Third Quarter 2022 Results
- 141
Regulatory News:
Highlights Q3 2022:
› Revenue was USD 188.3 million, within the guided USD 182-192 million, up 11% year-on-year (YoY) and flat quarter-on-quarter (QoQ)
› Consistently strong demand across X-FAB’s key end markets, with bookings totaling USD 217.0 million, up 9% YoY, while industrial and silicon carbide revenues were at record levels
› EBITDA at USD 9.2 million with a 4.9% margin due to the USD 36.8 million one-off impact from arbitration proceedings; excluding this exceptional item, EBITDA would have been USD 46.0 million with a margin of 24.4% above the guided 20-24%
› EBIT was USD -9.9 million and would have been USD 26.9 million excluding the one-off item
Outlook:
› Q4 2022 revenue is expected to be in the range of USD 180-190 million with an EBITDA margin in the range of 20-24%, reflecting the temporary impact of a facilities-related incident, which caused a power outage at the Malaysian site in early October, and based on an average exchange rate of 1.00 USD/Euro. Full-year revenues are expected to come in at a range of USD 735-745 million.
› Q1 2023 revenue is expected to come in at a range of USD 205-220 million following full operational recovery of X-FAB Sarawak, Malaysia, and based on a price increase effective January 2023.
Revenue breakdown per quarter:
in millions of USD |
Q4 2020 |
Q1 2021 |
Q2 2021 |
Q3 2021 |
Q4 2021 |
Q1 2022 |
Q2 2022 |
Q3 2022 |
Q3 y-o-y
|
Automotive |
65.4 |
83.5 |
82.8 |
81.5 |
83.8 |
89.7 |
98.3 |
96.9 |
19% |
Industrial |
27.3 |
32.4 |
35.2 |
38.3 |
39.7 |
41.4 |
42.5 |
46.7 |
22% |
Medical |
12.0 |
8.7 |
10.4 |
14.3 |
14.5 |
13.7 |
13.9 |
13.5 |
-6% |
Subtotal core business |
104.7 |
124.6 |
128.4 |
134.1 |
138.0 |
144.9 |
154.7 |
157.0 |
17% |
77.1% |
80.1% |
79.8% |
79.3% |
80.1% |
81.1% |
81.9% |
83.4% |
|
|
CCC* |
30.9 |
30.6 |
32.4 |
34.7 |
34.0 |
32.5 |
33.6 |
30.7 |
-11% |
Others |
0.3 |
0.3 |
0.1 |
0.3 |
0.3 |
1.2 |
0.6 |
0.6 |
|
Total revenues |
135.9 |
155.4 |
161.0 |
169.1 |
172.3 |
178.7 |
188.8 |
188.3 |
11% |
* Consumer, Communications & Computer
in millions of USD |
Q4 2020 |
Q1 2021 |
Q2 2021 |
Q3 2021 |
Q4 2021 |
Q1 2022 |
Q2 2022 |
Q3 2022 |
Q3 y-o-y
|
CMOS |
115.0 |
134.9 |
137.5 |
141.8 |
144.2 |
148.6 |
156.3 |
152.6 |
8% |
MEMS |
14.6 |
14.4 |
16.2 |
17.4 |
17.5 |
17.9 |
19.8 |
18.4 |
6% |
Silicon carbide |
6.3 |
6.1 |
7.2 |
9.9 |
10.6 |
12.1 |
12.8 |
17.4 |
76% |
Total revenues |
135.9 |
155.4 |
161.0 |
169.1 |
172.3 |
178.7 |
188.8 |
188.3 |
11% |
Business development
In the third quarter, X-FAB’s business continued to develop strongly. Customer demand remained at high levels despite current political and economic volatility.
Third quarter revenues amounted to USD 188.3 million, within the guided USD 182-192 million, up 11% year-on-year and flat quarter-on-quarter. The current Euro weakness created a headwind for X-FAB’s top line. At the same USD/Euro exchange rate as experienced in the respective comparable quarter, X-FAB’s revenues would have recorded a growth of 19% year-on-year and 2% quarter-on-quarter.
Revenues in X-FAB’s core markets – automotive, industrial, and medical – came in at USD 157.0 million, up 17% year-on-year and 2% quarter-on-quarter. Their share of the Group’s total revenues increased further to more than 83% reflecting the continued strength of these key end markets and the underlying transformation towards businesses with longer life cycles and higher value-add.
X-FAB’s automotive revenues in the third quarter were up 19% year-on-year and are expected to develop strongly going forward due to the rising trend of vehicle electrification. X-FAB’s high-voltage CMOS as well as silicon carbide (SiC) technologies continued to be in high demand. In the third quarter, SiC revenues reached a record level of USD 17.4 million, up 76% year-on-year.
In the third quarter, X-FAB also recorded all-time high industrial revenues at USD 46.7 million, up 22% year-on-year. The strong and consistent growth in this market is mainly driven by the industry’s transition to renewable and environmentally friendly energy sources, which keeps pushing demand for power semiconductors. Additionally, industrial automation to increase efficiency across all sectors is also contributing to the sustainable growth of X-FAB’s industrial business.
Third quarter revenues in the medical market were down 6% year-on-year due to normal fluctuations of medical prototyping revenues (-32%) while medical production revenues continued to grow steadily by 5%. With its combined CMOS and MEMS capabilities, X-FAB is uniquely positioned to support advances in healthcare increasingly achieved using semiconductor technology. This will drive the growth of X-FAB’s medical business in the long-term. In the third quarter, the growth in medical volume production revenues was mainly driven by lab-on-a-chip applications for DNA sequencing, temperature sensors for contactless thermometers as well as chips for ultrasound equipment.
X-FAB’s CCC business (Consumer, Communication & Computer) recorded revenues of USD 30.7 million, down 11% year-on-year and 9% quarter-on-quarter. The decrease relates to the legacy business still being produced at X-FAB France which has recently been decreasing at a faster pace and is expected to be fully replaced in the first quarter of 2023. The portion of the French site’s revenues based on X-FAB technologies went up to 56% in the third quarter.
Quarterly bookings came in at USD 217.0 million, up 9% year-on-year and 33% quarter-on-quarter with particularly strong order intake in automotive. Third quarter bookings already reflect the increased price level effective 2023, both for LTA (long-term agreements) and non-LTA customers. Additionally, the bookings growth also shows the high demand beyond the business that will be covered by long-term contracts. This includes orders for MEMS and more mature CMOS nodes.
Third quarter prototyping revenues came in at USD 22.8 million, down 11% year-on-year and up 11% quarter-on-quarter.
Prototyping and production revenue per quarter and end market:
in millions of USD |
Revenue |
Q3 2021 |
Q4 2021 |
Q1 2022 |
Q2 2022 |
Q3 2022 |
Q3 y-o-y
|
Automotive |
Prototyping |
3.5 |
3.6 |
5.0 |
4.1 |
3.3 |
-5% |
Production |
78.0 |
80.2 |
84.8 |
94.2 |
93.6 |
20% |
|
Industrial |
Prototyping |
12.9 |
11.5 |
11.0 |
9.2 |
11.1 |
-14% |
Production |
25.4 |
28.2 |
30.4 |
33.3 |
35.6 |
40% |
|
Medical |
Prototyping |
4.1 |
4.0 |
3.1 |
1.6 |
2.8 |
-32% |
Production |
10.2 |
10.6 |
10.7 |
12.4 |
10.7 |
5% |
|
CCC |
Prototyping |
4.8 |
4.5 |
4.3 |
5.0 |
5.0 |
4% |
Production |
29.9 |
29.5 |
28.2 |
28.6 |
25.7 |
-14% |
Operations update
In the third quarter, X-FAB continued to run its factories at full load and progressed to expand capacities in line with the delivery and availability of new tools. In times of universally limited resources, X-FAB’s stringent supply chain management as well as comprehensive recruiting activities contributed to seamless operations across all sites.
The silicon carbide business gained further traction. Driven by X-FAB’s streamlined onboarding process, which was introduced in the fourth quarter last year to speed up customers’ time-to-market, the number of new projects has been increasing significantly, and X-FAB keeps attracting new customers. In response to strong demand, X-FAB accelerated its activities to expand SiC processing capacity and plans to more than double the current run rate by the end of 2023. The delivery of additional tools to increase SiC epitaxy capacity is still expected this year.
On October 2, 2022, the Malaysian site experienced a major facilities-related power outage. Thanks to the high level of commitment of the teams on site, the damage was quickly contained, and comprehensive repair and re-qualifications of production started immediately. The incident is expected to impact fourth quarter revenues by approximately USD 15 million, which is taken into account in the respective guidance.
Quarterly capital expenditures came in at USD 40.9 million, up 87% against the same quarter last year. Full year capital expenditures are expected to come in at approximately USD 200 million but could eventually be lower due to prolonged and uncertain lead times for the delivery of new equipment ordered.
Financial update
The outcome of arbitration proceedings with a supplier (see press release dated Oct 6, 2022) had a one-off negative impact of USD 36.8 million on X-FAB’s third quarter earnings. EBITDA was USD 9.2 million with a margin of 4.9% versus the guided 20-24%. Excluding this non-recurring item, which was recorded under “Other income and expenses”, the EBITDA margin would have been 24.4%. Third quarter operating profit (EBIT) came in at USD -9.9 million compared to USD 26.9 million excluding the impact of the arbitration, which has now been completed and fully accounted for.
Cash and cash equivalents at the end of the third quarter amounted to USD 327.5 million, up 30.6% compared to the previous quarter end.
While the current Euro weakness created a headwind for the top line the natural hedging of the business makes X-FAB’s profitability largely independent from US-Dollar/Euro exchange rate fluctuations. At a constant USD/Euro exchange rate of 1.18 as experienced in the previous year’s quarter, the EBITDA margin would have been 0.3 percentage points higher.
Management comments
Rudi De Winter, CEO of X-FAB Group, said: “I am very excited about how well X-FAB is positioned and I could not be more convinced of our long-term growth trajectory. With the technologies and expertise X-FAB offers we address exactly those segments of the semiconductor industry that are forecast to show the strongest growth over the next decade, in particular the automotive part of our business, and we see this reflected in the consistently strong customer interest with bookings beyond our capability to produce. The urgent need for green mobility and sustainable energy keeps driving demand for X-FAB’s silicon carbide and high-voltage CMOS technologies while X-FAB also benefits from rising demand for novel medical applications that increasingly rely on semiconductor technologies as we provide them. I see X-FAB well on track to reach USD 1 billion revenues by 2024 with an EBITDA margin of 30% despite the currently challenging macro-economic environment.”
X-FAB Quarterly Conference Call
X-FAB’s third quarter results will be discussed in a live conference call on Thursday, October 27, 2022, at 6.30 p.m. CEST. The conference call will be in English. Please register in advance of the conference using the following link: https://cossprereg.btci.com/prereg/key.process?key=PYN6XUTKT.
The conference call will be available for replay for ten days following the event. Please call +1 617 801 6888 and enter the following passcode: 95428830.
The fourth quarter 2022 results will be communicated on February 9, 2023.
About X-FAB
X-FAB is the leading analog/mixed-signal and MEMS foundry group manufacturing silicon wafers for automotive, industrial, consumer, medical and other applications. Its customers worldwide benefit from the highest quality standards, manufacturing excellence and innovative solutions by using X-FAB’s modular CMOS processes in geometries ranging from 1.0 to 0.13 µm, and its special silicon carbide and MEMS long-lifetime processes. X-FAB’s analog-digital integrated circuits (mixed-signal ICs), sensors and micro-electro-mechanical systems (MEMS) are manufactured at six production facilities in Germany, France, Malaysia and the U.S. X-FAB employs approx. 4,000 people worldwide. For more information, please visit www.xfab.com.
Forward-looking information
This press release may include forward-looking statements. Forward-looking statements are statements regarding or based upon our management’s current intentions, beliefs or expectations relating to, among other things, X-FAB’s future results of operations, financial condition, liquidity, prospects, growth, strategies or developments in the industry in which we operate. By their nature, forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results or future events to differ materially from those expressed or implied thereby. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein.
Forward-looking statements contained in this press release regarding trends or current activities should not be taken as a report that such trends or activities will continue in the future. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless legally required. You should not place undue reliance on any such forward-looking statements, which speak only as of the date of this press release.
The information contained in this press release is subject to change without notice. No re-report or warranty, express or implied, is made as to the fairness, accuracy, reasonableness, or completeness of the information contained herein and no reliance should be placed on it.
Condensed Consolidated Statement of Profit and Loss
in thousands of USD |
Quarter
ended
unaudited |
Quarter
ended
unaudited |
Quarter
ended
unaudited |
Nine months
ended
unaudited |
Nine months
ended
unaudited |
Revenue |
188,336 |
169,097 |
188,832 |
555,831 |
485,471 |
Revenues in USD in % |
59 |
60 |
58 |
59 |
64 |
Revenues in EUR in % |
41 |
40 |
42 |
41 |
35 |
Cost of sales |
-142,432 |
-129,773 |
-142,870 |
-420,724 |
-369,422 |
Gross Profit |
45,904 |
39,323 |
45,962 |
135,107 |
116,049 |
Gross Profit margin in % |
24.4 |
23.3 |
24.3 |
24.3 |
23.9 |
|
|
|
|
|
|
Research and development expenses |
-9,917 |
-7,751 |
-9,920 |
-30,596 |
-24,925 |
Selling expenses |
-1,844 |
-1,969 |
-1,968 |
-5,961 |
-6,095 |
General and administrative expenses |
-8,860 |
-8,320 |
-10,495 |
-28,087 |
-24,120 |
Rental income and expenses from investment properties |
-328 |
422 |
187 |
151 |
1,717 |
Other income and other expenses |
-34,897 |
-340 |
257 |
-34,310 |
374 |
Operating profit |
-9,943 |
21,366 |
24,023 |
36,304 |
63,000 |
Finance income |
10,219 |
5,166 |
8,585 |
25,896 |
12,920 |
Finance costs |
-13,690 |
-6,027 |
-24,153 |
-46,332 |
-16,299 |
Net financial result |
-3,471 |
-861 |
-15,567 |
-20,436 |
-3,379 |
|
|
|
|
|
|
Profit before tax |
-13,413 |
20,505 |
8,456 |
15,868 |
59,621 |
Income tax |
-1,608 |
1,296 |
-1,539 |
-4,596 |
1,691 |
Profit for the period |
-15,021 |
21,801 |
6,917 |
11,272 |
61,313 |
|
|
|
|
|
|
Operating profit (EBIT) |
-9,943 |
21,366 |
24,023 |
36,304 |
63,000 |
Depreciation |
19,123 |
19,076 |
18,442 |
56,372 |
56,345 |
EBITDA |
9,180 |
40,442 |
42,465 |
92,676 |
119,345 |
EBITDA margin in % |
4.9 |
23.9 |
22.5 |
16.7 |
24.6 |
|
|
|
|
|
|
Earnings per share at the end of period |
-0.11 |
0.17 |
0.05 |
0.09 |
0.47 |
Weighted average number of shares |
130,631,921 |
130,631,921 |
130,631,921 |
130,631,921 |
130,631,921 |
|
|
|
|
|
|
EUR/USD average exchange rate |
1.00955 |
1.17954 |
1.06719 |
1.06620 |
1.19661
|
Amounts in the financial tables provided in this press release are rounded to the nearest thousand except when otherwise indicated, rounding differences may occur.
Condensed Consolidated Statement of Financial Position
in thousands of USD |
Quarter ended
|
Quarter ended
|
Year ended
|
ASSETS |
|
|
|
Non-current assets |
|
|
|
Property, plant, and equipment |
419,827 |
330,295 |
340,670 |
Investment properties |
7,952 |
8,120 |
8,310 |
Intangible assets |
7,269 |
3,996 |
4,034 |
Other non-current assets |
6 |
38 |
28 |
Deferred tax assets |
44,912 |
36,097 |
45,645 |
Total non-current assets |
479,967 |
378,546 |
398,687 |
|
|
|
|
Current assets |
|
|
|
Inventories |
204,278 |
172,560 |
181,014 |
Trade and other receivables |
82,595 |
66,530 |
73,689 |
Other assets |
47,118 |
38,784 |
43,354 |
Cash and cash equivalents |
327,468 |
226,013 |
290,187 |
Total current assets |
661,459 |
503,886 |
588,244 |
|
|
|
|
TOTAL ASSETS |
1,141,425 |
882,432 |
986,931 |
|
|
|
|
EQUITY AND LIABILITIES |
|
|
|
Equity |
|
|
|
Share capital |
432,745 |
432,745 |
432,745 |
Share premium |
348,709 |
348,709 |
348,709 |
Retained earnings |
-24,625 |
-58,671 |
-36,154 |
Cumulative translation adjustment |
185 |
-587 |
-559 |
Treasury shares |
-770 |
-770 |
-770 |
Total equity attributable to equity holders of the parent |
756,243 |
721,426 |
743,971 |
|
|
|
|
Non-controlling interests |
0 |
348 |
365 |
|
|
|
|
Total equity |
756,243 |
721,774 |
744,335 |
|
|
|
|
Non-current liabilities |
|
|
|
Non-current loans and borrowings |
65,234 |
32,251 |
39,917 |
Other non-current liabilities and provisions |
3,686 |
4,153 |
5,686 |
Total non-current liabilities |
68,921 |
36,404 |
45,602 |
|
|
|
|
Current liabilities |
|
|
|
Trade payables |
41,282 |
31,204 |
41,364 |
Current loans and borrowings |
191,519 |
17,647 |
87,114 |
Other current liabilities and provisions |
83,460 |
75,404 |
68,515 |
Total current liabilities |
316,261 |
124,255 |
196,993 |
|
|
|
|
TOTAL EQUITY AND LIABILITIES |
1,141,425 |
882,432 |
986,931 |
Condensed Consolidated Statement of Cash Flow
in thousands of USD |
Quarter
ended
unaudited |
Quarter
ended
unaudited |
Quarter
ended
unaudited |
Nine months
ended
unaudited |
Nine months
ended
unaudited |
Income before taxes |
-13,413 |
20,505 |
8,456 |
15,868 |
59,621 |
|
|
|
|
|
|
Reconciliation of net income to cash flow arising from operating activities: |
18,392 |
18,131 |
36,295 |
75,631 |
51,801 |
Depreciation and amortization, before effect of grants and subsidies |
19,123 |
19,076 |
18,442 |
56,372 |
56,345 |
Recognized investment grants and subsidies netted with depreciation and amortization |
-820 |
-850 |
-841 |
-2,535 |
-2,539 |
Interest income and expenses (net) |
967 |
-139 |
13,015 |
14,165 |
-379 |
Loss/(gain) on the sale of plant, property, and equipment (net) |
-1,822 |
80 |
-19 |
-1,998 |
-312 |
Other non-cash transactions (net) |
945 |
-36 |
5,698 |
9,628 |
-1,313 |
|
|
|
|
|
|
Changes in working capital: |
8,067 |
15,565 |
-21,335 |
-45,451 |
-17,494 |
Decrease/(increase) of trade receivables |
7,883 |
1,439 |
-15,479 |
-16,232 |
-10,796 |
Decrease/(increase) of other receivables & prepaid expenses |
1,913 |
10,743 |
-918 |
-4,804 |
-811 |
Decrease/(increase) of inventories |
-5,852 |
-10,324 |
-3,062 |
-23,263 |
-18,848 |
(Decrease)/increase of trade payables |
-3,080 |
4,446 |
-3,341 |
-8,436 |
4,845 |
(Decrease)/increase of other liabilities |
7,203 |
9,261 |
1,466 |
7,284 |
8,117 |
|
|
|
|
|
|
Income taxes (paid)/received |
-342 |
-220 |
-108 |
-557 |
-1,967 |
|
|
|
|
|
|
Cash Flow from operating activities |
12,704 |
53,981 |
23,308 |
45,491 |
91,962 |
|
|
|
|
|
|
Cash Flow from investing activities: |
|
|
|
|
|
Payments for property, plant, equipment & intangible assets |
-40,918 |
-21,932 |
-36,760 |
-126,524 |
-45,849 |
Payments for investments |
-204 |
0 |
0 |
-204 |
0 |
Payments for loan investments to related parties |
-45 |
-72 |
-35 |
-193 |
-201 |
Proceeds from loan investments related parties |
70 |
42 |
62 |
230 |
166 |
Proceeds from sale of property, plant, and equipment |
1,887 |
47 |
64 |
2,115 |
449 |
Interest received |
394 |
451 |
275 |
906 |
1,390 |
|
|
|
|
|
|
Cash Flow used in investing activities |
-38,815 |
-21,464 |
-36,393 |
-123,670 |
-44,046 |
Condensed Consolidated Statement of Cash Flow – con’t
in thousands of USD |
Quarter
ended
unaudited |
Quarter
ended
unaudited |
Quarter
ended
unaudited |
Nine months
ended
unaudited |
Nine months
ended
unaudited |
Cash Flow from (used in) financing activities: |
|
|
|
|
|
Proceeds from loans and borrowings |
129,728 |
310 |
15,281 |
152,270 |
4,789 |
Repayment of loans and borrowings |
-1,892 |
-8,561 |
-1,367 |
-6,062 |
-20,411 |
Receipts of sale & leaseback arrangements |
0 |
0 |
0 |
7,723 |
0 |
Payments of lease installments |
-1,362 |
-1,335 |
-1,258 |
-4,379 |
-4,037 |
Receipt of government grants and subsidies |
512 |
0 |
0 |
512 |
0 |
Interest paid |
-13,503 |
-312 |
-432 |
-14,074 |
-1,010 |
Distribution to non-controlling interests |
0 |
0 |
0 |
-11 |
-12 |
|
|
|
|
|
|
Cash Flow from (used in) financing activities |
113,484 |
-9,898 |
12,224 |
135,979 |
-20,681 |
|
|
|
|
|
|
Effect of changes in foreign currency exchange rates on cash |
-10,734 |
-1,715 |
-7,581 |
-20,519 |
-7,089 |
Increase/(decrease) of cash and cash equivalents |
87,373 |
22,619 |
-861 |
57,800 |
27,235 |
Cash and cash equivalents at the beginning of the period |
250,828 |
205,109 |
259,271 |
290,187 |
205,867 |
Cash and cash equivalents at the end of the period |
327,468 |
226,013 |
250,828 |
327,468 |
226,013 |
###
View source version on businesswire.com: https://www.businesswire.com/news/home/20221027005784/en/